Author: Lars Lengquist

TV4 morning show: Report: New Drugs Are Not Reaching All Breast Cancer Patients

Advances in breast cancer research are providing entirely new opportunities to diagnose and treat the most common cancer among women. Today, the Breast Cancer Association is releasing a report on access to the advanced diagnostic methods needed to determine whether a patient will benefit from specific medications, known as precision diagnostics. Susanne Dieroff Hay, Chair of the Breast Cancer Association, and Johan Hartman, tumor pathologist at Karolinska University Hospital, share their insights.

Unilabs Sverige and St. Göran’s Hospital are soon adopting Stratipath Breast for breast cancer risk profiling.

Johan Hartman is a guest at the Johnson & Johnson podcast “Vi forskar för livet” (“Research for Life”). The episode, titled “Precision Medicine is the Future of Healthcare – But Do We Have the Skills Needed?”

Article in Impact loop.

“We have the first product in this field approved for hospital use. But AI is advancing rapidly, so there will be competition, which is great. The market is large, so there’s room for more players.”

Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision Diagnostics

Stratipath is thrilled to announce a collaboration with Roche, the world’s largest biotechnology company and the global leader in in-vitro diagnostics.

Webinar: Prognostic Tools in Breast Cancer Care

In collaboration with iBreastBook, Johan Hartman, co-founder of Stratipath, participated in a webinar focused on predictive and prognostic tools in breast cancer care. Johan delivered an insightful lecture on: ”AI-Based Image Analysis: A Cost-Effective Alternative to Genomic Profiling”. We were honored to have an excellent lineup of speakers and panelists who shared their expertise:– Abeer […]

Stratipath Joins Forces with Colombian Pathology Leaders to Advance Digital Pathology

Stratipath is thrilled to announce our active role in advancing Digital Pathology in Colombia, driven by the collaborative efforts between the Swedish Association of Pathology and the Colombian Association of Pathology. Our Co-founder and CMO, Professor Johan Hartman, has been at the forefront of these discussions, bringing invaluable insights from Sweden’s experience with Digital Pathology. […]

A new validation study on the prognostic performance of Stratipath Breast.

Stratipath is excited to announce the publication of a new validation study on the prognostic performance of Stratipath Breast—the first AI-based CE-marked medical device for risk stratification of breast cancer using routine H&E histopathology images.

Swelife conducted an interview with our Chief Medical Officer and co-founder Johan Hartman

Swelife conducted an interview with our Chief Medical Officer and co-founder Johan Hartman

Stratipath was honored with the Dream Award at the Techarenan Challenge in Almedalen.

Stratipath was honored with the Dream Award at the Techarenan Challenge in Almedalen.

Seminar – Almedalen. ”AI can predict relapse in breast cancer – How does this affect breast cancer care?”

Seminar – Almedalen. ”AI can predict relapse in breast cancer – How does this affect breast cancer care?”